{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T19:53:38Z","timestamp":1783022018641,"version":"3.54.6"},"reference-count":40,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Dermatology"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, is approved in Japan for adults with plaque, generalized pustular, and erythrodermic psoriasis who have inadequate response to conventional systemic therapies. In the Phase 3, open\u2010label POETYK PSO\u20104 (NCT03924427) trial, deucravacitinib was efficacious and well tolerated in Japanese patients with moderate to severe plaque psoriasis. This post hoc analysis of PSO\u20104 evaluated deucravacitinib efficacy and safety in greater detail in this patient population. Absolute Psoriasis Area and Severity Index (PASI), achievement of PASI thresholds of \u2264\u20091, \u2264\u20092, and \u2264\u20095, and PASI body region (head, trunk, upper limbs, lower limbs) and plaque characteristic (erythema, induration, desquamation) scores were evaluated over 52\u2009weeks. Response rates (PASI 75, PASI 90, and static Physician Global Assessment score of 0 [clear] or 1 [almost clear]) were evaluated based on prior use of systemic (biologic and nonbiologic) therapy and phototherapy. Efficacy was also evaluated in patients with scalp, fingernail, and palmoplantar psoriasis. Select safety events were reviewed. Deucravacitinib improved absolute PASI from Week 1, with improvements maintained through Week 52. Deucravacitinib\u2010treated patients achieved clinically meaningful improvements in PASI thresholds, with nearly half (47.6%) achieving PASI \u2264\u20091 at Week 52. Deucravacitinib also improved PASI body region and plaque characteristic scores, with improvements that occurred as early as Week 1 maintained through Week 52. Deucravacitinib was efficacious through Week 52 regardless of prior use of systemic therapy or phototherapy. Deucravacitinib was also efficacious in patients with scalp and fingernail psoriasis, and in the limited number with palmoplantar psoriasis. Serious adverse events, adverse events resulting in discontinuation, and shifts to Grade \u2265\u20093 laboratory abnormalities were rare over 52\u2009weeks. This analysis provides a more detailed characterization of Japanese patients with plaque psoriasis appropriate for deucravacitinib treatment and confirms that deucravacitinib is efficacious and well tolerated in this patient population.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Trial Registration:<\/jats:bold>\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/www.clinicaltrials.gov\">www.ClinicalTrials.gov<\/jats:ext-link>\n                    identifier: NCT03924427\n                  <\/jats:p>","DOI":"10.1111\/1346-8138.17744","type":"journal-article","created":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T05:48:09Z","timestamp":1745992089000},"page":"953-966","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Japanese Patients With Plaque Psoriasis: In\u2010Depth Analysis of Efficacy and Safety in the Phase 3\n                    <scp>POETYK PSO<\/scp>\n                    \u20104 Trial"],"prefix":"10.1111","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9526-1259","authenticated-orcid":false,"given":"Yukari","family":"Okubo","sequence":"first","affiliation":[{"name":"Department of Dermatology Tokyo Medical University  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8372-3754","authenticated-orcid":false,"given":"Akimichi","family":"Morita","sequence":"additional","affiliation":[{"name":"Department of Geriatric and Environmental Dermatology Nagoya City University Graduate School of Medical Sciences  Nagoya Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8568-4349","authenticated-orcid":false,"given":"Shinichi","family":"Imafuku","sequence":"additional","affiliation":[{"name":"Department of Dermatology Faculty of Medicine, Fukuoka University Hospital  Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3743-135X","authenticated-orcid":false,"given":"Yayoi","family":"Tada","sequence":"additional","affiliation":[{"name":"Department of Dermatology Teikyo University School of Medicine  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuki","family":"Tsuritani","sequence":"additional","affiliation":[{"name":"Immunology Medical Strategy Bristol Myers Squibb K.K.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqiu","family":"Shao","sequence":"additional","affiliation":[{"name":"Biometrics Bristol Myers Squibb  Princeton New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoran","family":"Popmihajlov","sequence":"additional","affiliation":[{"name":"Clinical Development Bristol Myers Squibb  Princeton New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Napoli","sequence":"additional","affiliation":[{"name":"WW Medical I&amp;F Bristol Myers Squibb  Princeton New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Hippeli","sequence":"additional","affiliation":[{"name":"Biometrics Bristol Myers Squibb  Princeton New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5722-854X","authenticated-orcid":false,"given":"Katsuyoshi","family":"Habiro","sequence":"additional","affiliation":[{"name":"Immunology Medical Strategy Bristol Myers Squibb K.K.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7845-6698","authenticated-orcid":false,"given":"Mamitaro","family":"Ohtsuki","sequence":"additional","affiliation":[{"name":"Department of Dermatology Jichi Medical University  Tochigi Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,4,30]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.82"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-006450"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaw1736"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13466"},{"key":"e_1_2_10_6_1","unstructured":"\u201cSotyktu [Package Insert] \u201d(Bristol Myers Squibb 2022)."},{"key":"e_1_2_10_7_1","unstructured":"\u201cSotyktu [Package Insert] \u201d(Bristol Myers Squibb K.K. 2022)."},{"key":"e_1_2_10_8_1","unstructured":"\u201cSotyktu [Product Monograph] \u201d(Bristol Myers Squibb Canada Co. 2022)."},{"key":"e_1_2_10_9_1","unstructured":"\u201cSotyktu [Product Information] \u201d(Bristol Myers Squibb Australia Pty. Ltd. 2022)."},{"key":"e_1_2_10_10_1","unstructured":"\u201cSotyktu [European Summary of Product Characteristics] \u201d(Bristol Myers Squibb EEIG 2023)."},{"key":"e_1_2_10_11_1","unstructured":"\u201cSotyktu [Package Insert] \u201d(BMS Korea Pharmaceuticals Co. 2023)."},{"key":"e_1_2_10_12_1","unstructured":"\u201cSotyktu [Package Insert] \u201d(Bristol Myers Squibb (China) Investment Co. Ltd. 2023)."},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b00444"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.07.002"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.08.061"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.17074"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3245"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15777"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-020-00475-8"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15340"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2017.1395794"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16691"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18333"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16104"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12589"},{"key":"e_1_2_10_26_1","unstructured":"A.Oakley \u201cPASI Score \u201dhttps:\/\/dermnetnz.org\/topics\/pasi\u2010score#(2009)."},{"key":"e_1_2_10_27_1","unstructured":"E.West \u201cWhat to Know About the PASI Score \u201dhttps:\/\/www.medicalnewstoday.com\/articles\/pasi\u2010score(2021)."},{"key":"e_1_2_10_28_1","unstructured":"E.Mallard \u201cWhat Is the PASI Score for Psoriasis?\u201dhttps:\/\/www.healthcentral.com\/article\/what\u2010is\u2010the\u2010pasi\u2010score(2025)."},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.17038"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16737"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-024-02028-1"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.11.060"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16740"},{"key":"e_1_2_10_34_1","doi-asserted-by":"crossref","unstructured":"M.Lebwohl M.Gooderham R. B.Warren et\u00a0al. \u201cDeucravacitinib an Oral Selective Allosteric Tyrosine Kinase 2 Inhibitor in Moderate to Severe Plaque Psoriasis: Absolute PASI Outcomes Over 52\u2009Weeks in the Phase 3 POETYK PSO\u20101 Trial \u201dposter presented at Quadrennial World Congress of Dermatology Singapore July 3\u20138 2023.","DOI":"10.25251\/skin.7.supp.239"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae406"},{"key":"e_1_2_10_36_1","doi-asserted-by":"crossref","unstructured":"R. B.Warren A. W.Armstrong M.Gooderham et\u00a0al. \u201cDeucravacitinib an Oral Selective Tyrosine Kinase 2 Inhibitor in Moderate to Severe Plaque Psoriasis: 52\u2010Week Efficacy Results From the Phase 3 POETYK PSO\u20101 and POETYK PSO\u20102 Trials [Oral Presentation] \u201dpresented at The European Academy of Dermatology and Venereology Congress September 29\u2013October 2 (2021).","DOI":"10.1136\/annrheumdis-2022-eular.1377"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.5114\/ada.2020.94835"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-021-01080-z"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19925"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2024.4688"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15803"}],"container-title":["The Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.17744","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/1346-8138.17744","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.17744","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T14:52:15Z","timestamp":1772981535000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1346-8138.17744"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,30]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1111\/1346-8138.17744"],"URL":"https:\/\/doi.org\/10.1111\/1346-8138.17744","archive":["Portico"],"relation":{},"ISSN":["0385-2407","1346-8138"],"issn-type":[{"value":"0385-2407","type":"print"},{"value":"1346-8138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,30]]},"assertion":[{"value":"2025-01-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}